

Applicant : Nariyoshi Shinomiya et al.
Appln. No. : 10/599,327
Page : 2

Amendments to Claims

In the Claims:

Prior to further examination of this application, please amend the claims as shown below.

1. (Canceled)

2. (*Previously presented*) The RNAi molecule of claim 4 that is a single stranded siRNA that forms a hairpin structure.

3. (*Previously presented*) The RNAi molecule of claim 4 that is a double stranded siRNA.

4. (*Currently amended*) An interfering RNA (RNAi) molecule that comprises SEQ ID NO:15, wherein the RNAi is between about 19 and about 29 nucleotides in length.

- 5-7. (Canceled)

8. (*Previously presented*) A DNA molecule encoding the RNAi molecule of claim 4.

9. (*Previously presented*) An expression construct comprising DNA that encodes the RNAi molecule of claim 4 operatively linked to a promoter that drives the expression of said RNAi molecule in a c-met-expressing cell.

10. (*Original*) An expression construct comprising the DNA molecule of claim 8.

Applicant : Nariyoshi Shinomiya et al.
Appln. No. : 10/599,327
Page : 3

11. *(Currently amended)* The expression construct of claim 9, wherein [[a]] the promoter is one that drives the expression of said RNAi molecule in a c-met-expressing tumor or cancer cell.
12. *(Previously presented)* The expression construct of claim 11 wherein the promoter is a polIII promoter.
13. *(Original)* The expression construct of claim 12 wherein the polIII promoter is a U6 promoter.
14. *(Previously presented)* A viral vector comprising the expression construct of claim 9.
15. *(Original)* The viral vector of claim 14 that is a transient expression vector.
16. *(Previously presented)* The viral vector of claim 14 that is a stable expression vector.
17. *(Previously presented)* The viral vector of claim 14 that is an adenoviral vector.
18. *(Original)* The adenoviral vector of claim 17 that is an Ad5 viral vector.
- 19-37. *(Canceled)*

Applicant : Nariyoshi Shinomiya et al.
Appln. No. : 10/599,327
Page : 4

38. (*Previously presented*) A method of treating a c-met⁺ tumor or cancer in a subject, comprising administering to the subject by an effective route, an amount of the viral vector of claim 14 effective for inhibiting expression of c-met and thereby (i) inhibiting the growth, invasion or metastasis of cells of said tumor or cancer, or (ii) killing said tumor or cancer cells.

39-47. (*Canceled*)

48. (*Previously presented*) The method of claim 38 wherein the tumor or cancer is glioblastoma, prostate or gastric.

49. (*Previously presented*) A method of treating a c-met⁺ tumor or cancer in a subject, comprising administering to the subject by an effective route, an amount of the viral vector of claim 19 effective for inhibiting expression of c-met and thereby (i) inhibiting the growth, invasion or metastasis of cells of said tumor or cancer, or (ii) killing said tumor or cancer cells.

50. (*Previously presented*) The method of claim 49 wherein the tumor or cancer is glioblastoma, prostate or gastric.